Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Evommune (EVMN) Revenue (2024 - 2025)

Evommune (EVMN) has disclosed Revenue for 2 consecutive years, with -$9000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Revenue rose 47.06% to -$9000.0 in Q3 2025 year-over-year; TTM through Dec 2025 was -$26000.0, a N/A change, with the full-year FY2025 number at $13.0 million, up 85.71% from a year prior.
  • Revenue was -$9000.0 for Q3 2025 at Evommune, up from -$17000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of -$9000.0 in Q3 2025 to a low of -$17000.0 in Q3 2024.